Backtracking Subclonal Mutations Of TP53 In Myelodysplasia (MDS) With Del(5q) With Next-Generation Sequencing (NGS)
Lodé L, Ménard A, Loirat M, et al.
Key Points:
TP53 mutations associated with worse survival outcomes in myelodysplastic syndromes (MDS)
Utilizing highly sensitive molecular assay, authors's experiments determined rate of TP53 mutations in low risk MDS patients with del(5q) at follow-up or progression after classical treatments
TP53 mutation present in 43% of patients at time of diagnosis
Analyses positive in 61% of samples collected at follow-up or progression
Complete clonal evolution consecutive to treatment with lenalidomide demonstrated in 11 cases
Implications:
- Early detection of TP53 mutant subclones by NGS assay in patients with low risk MDS may guide therapeutic decisions
View the original abstract on the ASH website.
